THE SOUTH AFRICAN
DEPRESSION AND ANXIETY
GROUP

facebooktwitter

IN THE WORKPLACE

New Research on Depression in the Workplace.

For more information please click here

business

SADAG NEWSLETTER

To subscribe to SADAG's newsletter, click here

JOURNAL

Mental Health Matters Journal for Psychiatrists & GP's

MHM September 207x300

Click here for more info on articles & how to subscribe

SPEAKING BOOKS

suicide book

Literacy is a luxury that many of us take for granted.  We depend on written communication for information, guidance, and access to heath care information That is why SADAG created SPEAKING BOOKS and revolutionized the way information is delivered to low literacy communities. It's exactly what it sounds like.a book that talks to the reader in his or her local  language, delivering critical information in an interactive, and educational way.

The customizable 16-page book, accompanied by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood..

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 30 titles, such as TB, Malaria, Polio, Vaccines for over 30 countries.

depression book

By RICK NAUERT PHD Senior News Editor
Reviewed by John M. Grohol, Psy.D. on August 12, 2014

schizophrenia drugs
 
A recently published study suggests a new class of drug may act as a dimmer switch to control schizophrenia.

The approach is heralded as a method to manage the symptoms of schizophrenia without some of the side effects associated with current anti-psychotic medicines.
Schizophrenia is a chronic, severe, and disabling brain disorder that affects one percent of the general population; however, it occurs in 10 percent of people who have a first-degree relative with the disorder, such as a parent, brother, or sister.

The medical condition disturbs a person’s ability to think, feel, and act and is associated with distressing symptoms including hallucinations and delusions.

Researcher Dr. Rob Lane said all current anti-psychotic medicines block the action of dopamine, a neurotransmitter, at a brain protein called the dopamine D2 receptor, resulting in serious side effects.

“These medications frequently result in serious side effects because this protein is also important for the control of movement. The side-effects can sometimes persist even after the patient has stopped taking the medication,” said Lane.

Co-lead researcher Arthur Christopoulos, Ph.D., said gaining a better understanding of the biology of schizophrenia will lead to more effective drugs.

“The idea behind our research is to develop a drug that doesn’t completely block dopamine. We found a molecule that, rather than blocking the effect of dopamine at the D2 receptor, acts to subtly dial down dopamine’s effect, a bit like a dimmer switch,” Christopoulos said.

“This means that if we can get just the right amount of dial-down, we could treat the symptoms of the disease and avoid some of these side-effects.

“We’re a long way yet from developing a drug, but our dimmer switch approach to controlling schizophrenia means it’s conceivable we could have a whole new class of anti-psychotics in the future.”

As published in the journal Nature Chemical Biology, the research team also found a unique twist with the molecule, its mechanism of action changed depending on the arrangement of the D2 receptor in the brain.

Lane believes this represents a new approach to develop anti-psychotics, as it gives researchers more information about the protein involved in the disease.

“This extra information will help researchers develop new drugs that target the protein.”

Our Sponsors

Our Partners